Pharmaceutical industry: Luther advises Lyomark Pharma on sale of Lyocontract GmbH to US PE investor

Leipzig/Ilsenburg (Harz), 18 June 2024 – Lyomark Pharma GmbH and the other minority shareholders have sold their shares in Lyocontract GmbH, a contract development and manufacturing organisation (CDMO) for liquid and lyophilised parenteral drugs. Lyomark Pharma GmbH was advised on the transaction by Luther Rechtsanwaltsgesellschaft. The buyer is the US private equity investor Great Point Partners, LLC.


Lyomark Pharma GmbH from Oberhaching (Bavaria) and the other co-shareholders have sold their shares in Lyocontract GmbH as part of an international sales process. For Lyomark Pharma, the sale marks the completion of the successful development and market establishment of a highly specialised pharmaceutical production service provider. The acquisition by Great Point Partners (GPP) is the first investment made by GPP's London-based European team. Lyocontract will be supported in its further transatlantic expansion.

Luther's transaction team, experienced in the pharmaceutical and life science sector, provided comprehensive legal advice on the transaction.

About Lyomark Pharma GmbH:

Lyomark Pharma was founded in 1989 in Oberhaching near Munich (Bavaria) as a contract and active ingredient manufacturer for niche products. The medium-sized company is a service provider of lyophilised and liquid sterile products and has been established in this field in the pharmaceutical industry for over 25 years.

In addition to manufacturing, the services for pharmaceutical customers also include the provision and maintenance of dossiers and the submission of national and international marketing authorisations for well-known pharmaceutical companies.


About Lyocontract GmbH:

Lyocontract operates a state-of-the-art pharmaceutical manufacturing facility for the production of liquid and lyophilised parenteral drugs in vials, which are used worldwide for both clinical and commercial purposes. The company also carries out analyses/quality control of raw materials and excipients and finished products as well as in-process control of ongoing production and offers packaging of medicinal products.

Lyocontract received manufacturing authorisation and GMP certification for its site in Ilsenburg (Saxony-Anhalt) in 2012 and has since gained the trust of numerous customers in Germany and abroad. Lyomark Pharma GmbH acquired the majority shareholding in Lyocontract GmbH in August 2017.


On behalf of Lyomark Pharma GmbH:

Luther, Corporate/M&A: Denis Ullrich (Partner, lead), Dr Björn Simon (Partner), Dr Johannes Becker (Counsel), Jan-Christian Schmid (Senior Associate), Dr Sven C. Stumm, MJur (Senior Associate), Jacqueline Dutz (Associate), Paul Jakob Kurz (Associate), Felix Imelmann (Associate)

Luther, Health Care Commercial & Regulatory: Anne Biebler (Senior Associate)

Luther, Labour Law: Daniel Zintl (Partner), Dr Delia Jusciak (Associate)

Luther, Environment, Planning, Regulatory: Dr Sabrina Desens (Partner), Dr Clara Schulze Velmede (Associate)

Luther, Antitrust/FDI: Prof. Dr Christian Burholt, LL.M. (Partner), Lara Zölck (Associate)

On behalf of GPP:

McDermott Will & Emery Rechtsanwälte Steuerberater LLP: Dr Jan Hückel (lead, Düsseldorf), Dr Alexander Hoppe, LL.M.